An examination of the FDA's database on adverse events found a greater than twofold increase in pancreatic cancer among type 2 diabetes patients using Byetta or Januvia. Byetta was also associated with an increase in reported cases of thyroid cancer. The findings aren't conclusive but do indicate a need for further investigation, the researchers reported in Gastroenterology.

Full Story:
HealthDay News

Related Summaries